[Federal Register Volume 75, Number 108 (Monday, June 7, 2010)]
[Notices]
[Pages 32185-32186]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-13597]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of
[[Page 32186]]
federally-funded research and development. Foreign patent applications
are filed on selected inventions to extend market coverage for
companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Software System for Analysis of Extremely Large Experimental Dataset
and Multidimensional Drug Discovery
Description of Invention: This invention is a computer software
suite that will enable its user to investigate extremely large
experimental datasets in a simple yet multidimensional manner. The
software, Omnimorph, allows multidimensional investigation of any form
of data including experimental datasets in biomedical science using
either gene arrays or proteomics. Omnimorph allows the user to look for
extremely subtle correlated differences between experimental datasets
which will allow the investigator to discover far more drug- or
disease-specific factors than other analytical methods currently used.
The software of present invention has been employed in the targeted
discovery of G protein-independent receptor-based pharmacotherapeutics.
These discoveries represent an entirely new GPCR-based G protein-
independent pharmacopeia. Therefore, the Omnimorph is not only newly
developed software, but the Omnimorph suite can also be used as a
simple and unbiased tool to detect novel and unexpected modes of GPCR-
based drug actions. This could potentially alter the way drugs are
developed and screened in the future.
Applications:
Development and screen for pharmaceutical drugs.
Biomedical research.
Development Status:
The invention has been fully developed.
The software will be readily available if so requested.
Inventors: Stuart R. Maudsley et al. (NIA).
Patent Status: HHS Reference No. E-143-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing.
Licensing Contacts: Uri Reichman, PhD, MBA; 301-435-4616;
[email protected]; or Michael Shmilovich, Esq.; 301-435-5019;
[email protected].
Collaborative Research Opportunity: The National Institute on
Aging, Laboratory of Neurosciences-Receptor Pharmacology Unit, is
seeking statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
this technology. Please contact John Hewes, PhD at 301-435-3131 or
[email protected] for more information.
Sound Attenuation Canopy for Reducing Noise Transmitted Through
Suspended Ceilings
Description of Invention: Available for licensing and commercial
implementation in commercial facilities design and construction are
intellectual property rights covering a sound attenuation canopy for
reducing noise transmitted through suspended ceiling systems commonly
used in most office buildings. The canopy is designed to absorb sound
energy and effectively reduce the direct path of sound travelling
within open plenum suspended ceilings like those used in most office
building environments. The canopy can also act as an umbrella to shield
loose debris and dust which may be located in the plenum and
potentially fall when ceiling suspended return-air grilles are moved or
accessed. The canopy has an added benefit of reducing heating or
cooling loss which may naturally ventilate through the return air
plenum grille from a conditioned office space below. Also, the canopy
controls leakage of heating and cooling, reducing loads on the central
building systems thereby lessening energy costs and extending the life-
cycle of the building's physical plant.
The canopy does not impede natural air flow for ventilating the
plenum cavity but deters the spread of smoke or fire between the plenum
and the office space below. The canopy can also act as a secondary air
balancer or K Factor balancer to equate supply and return air to
control room temperature. The canopy is pliable and therefore allows
for ease of adjustment within varying plenum conditions as well as
readily installed in ceiling plenums.
Applications:
Building design and construction.
Sound attenuation.
Energy load reduction.
Inventors: Judit A. Quasney, Franklin Koh, John P. Jenkins, Robert
M. Alexander, Daniel P. O'Brien (NIAID).
Patent Status: U.S. Patent Application No. 12/764,872 filed 21 Apr
2010 (HHS Reference No. E-102-2010/0-US-01)
Licensing Status: Available for licensing.
Licensing Contact: Michael A. Shmilovich, Esq.; 301-435-5019;
[email protected].
Dated: June 1, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-13597 Filed 6-4-10; 8:45 am]
BILLING CODE 4140-01-P